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Liver transplantation for glycogen storage disease 
types I, III, and IV 
Abstract Glycogen storage disease (GSD) types I, III, and IV can be associated with 
severe liver disease. The possible development of hepatocellular carcinoma and/or hepatic 
failure make these GSDs potential candidates for liver transplantation. Early diagnosis 
and initiation of effective dietary therapy have dramatically improved the outcome of 
GSD type I by reducing the incidence of liver adenoma and renal insufficiency. Nine type 
I and 3 type III patients have received liver transplants because of poor metabolic control, 
multiple liver adenomas, or progressive liver failure. Metabolic abnormalities were cor-
rected in all GSD type I and type III patients, while catch-up growth was reported only in 
two patients. Whether liver transplantation results in reversal and/or prevention of renal 
disease remains unclear. Neutropenia persisted in both GSDIb patients post liver 
transplantation necessitating continuous granulocyte colony stimulating factor treatment. 
Thirteen GSD type IV patients were liver transplanted because of progressive liver cir-
rhosis and failure. All but one patient have not had neuromuscular or cardiac compli-
cations during follow-up periods for as long as 13 years. Four have died within a week 
and 5 years after transplantation. Caution should be taken in selecting GSD type IV 
candidates for liver transplantation because of the variable phenotype, which may include 
life-limiting extrahepatic manifestations. It remains to be evaluated, whether a genotype-
phenotype correlation exists for GSD type IV, which may aid in the decision making. 
Conclusion Liver transplant~tion should :be considered forpatierits with glycogen 
storage disease'fho havedev~loped liver malignancy. or hepatic fanNe,.~ndfor typeIY 
patients with thedassicaI and progressive hepatitform. .. 
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Introduction 
Glycogen storage diseases (GSDs) are inherited disor-
der:; in which the concentration and/or structure of 
glycogen in body tissues is abnormal: Essentially,. all 
known enzymes involved in the syntheSIS or degradatIOn 
of glycogen and glucose have been discovered to cause 
some type of GSD [4, 12, 17]. Liver and muscle have 
abundant quantities of glycogen and are the most 
common and seriously affected tissues. The GSDs (and 
associated enzymatic deficiencies) affecting the liver as 
the major organ are types I (glucose 6-phosphatase), III 
(debrancher), IV (brancher), VI (liver phosphorylase), 
and IX (phosphorylase b kinase), as well as glycogen 
synthase deficiency. The hepatic GSDs vary in the age of 
onset, progression, other organ involvement, and chmcal 
severity. Types I, III and IV can be associated with se-
vere liver disease. The possible development of hepato-
cellular carcinoma and/or hepatic failure makes these 
GSDs potential candidates for liver transplantation. 
GSD type Ia or von Gierke disease, is caused by a de-
ficiency of glucose-6-phosphatase activity. The clinical 
manifestations are growth retardation, hepatomegaly, 
hypoglycemia, lactic acidemia, hyperuricemia: and 
hyperlipidemia. A variant caused by a defect III the 
transport of glucose-6-phosphate (type Ib) has the a~­
ditional findings of neutropenia and impaired neutrophIl 
function, resulting in recurrent bacterial infections and 
oral and intestinal mucosa ulceration. Long-term com-
plications include gout, short stature, osteoporosis, renal 
disease, pulmonary hypertension and hepatic adenomas, 
which may undergo malignant transformation [4]. 
During the past 20 years, major progress has been 
made in managing this disorder. The current treatment 
of type I GSD is nocturnal nasogastric infusion of glu-
cose or orally administered uncooked cornstarch [3, 11]. 
With early diagnosis and initiation of treatment, the 
prognosis for type I GSD has improved dramatically. 
Normal growth and pubertal development may be ex-
pected, and patients who are now adults have fewer late 
complications. 
GSD type III is caused by a deficiency of glycogen 
deb ranching enzyme activity. The glycogen accumulated 
has a structure that resembles limit dextrin (glycogen 
with short outer chains). Most patients with GSD type 
III have both liver and muscle involvement (type IlIa). 
However, some patients (ca. 15% of all type III cases) 
have only liver involvement, without apparent muscle 
disease (type IIIb). Hepatomegaly, hypoglycemia, 
hyperlipidemia, and growth retardation usually improve 
with age and disappear after puberty. Overt liver cir-
rhosis and/or hepatocellular carcinoma may occur. 
In patients with disease involving muscle (type IlIa), 
muscle weakness, though minimal during childhood, can 
become predominant in adults; these patients show signs 
of neuromuscular involvement, with slowly progressive 
weakness and distal muscle wasting [4]. Treatment of 
type III disease consists of a high-protein diet; if hypo-
glycemia is present, frequent meals high in carbohy-
drates, with cornstarch supplements or nocturnal gastric 
drip feeding, constitute effective therapy. Currently there 
is no effective treatment for the progressive myopathy 
or cardiomyopathy. 
GSD type IV is caused by a deficiency of branching 
enzyme activity which results in the accumulation of 
glycogen with unbranched, long outer chains in the tis-
sues. This form of GSD typically presents in the I st year 
of life, with hepatosplenomegaly and failure to thrive. 
Hypoglycemia is rarely seen. Progressive liver ~irrhosis 
with portal hypertension, ascites, esophageal vances, and 
death usually occur before 5 years of age [4]. There are 
however, patients who have survived without apparent 
progressive liver disease [10, 16]. The neuromuscular 
system may also be involved. The presenti.ng sympto~l1S 
are hypotonia and muscle wasting. There IS no effectIve 
treatment for the disease. Severe cardiomyopathy, as the 
predominant symptom has been reported [20]. 
In this article, we review the indications for and report 
the long-term outcome of liver transplantation (LT) for 
GSD types I, III, and IV. We also define the criteria for 
L T in view of the recent advance in the treatment and 
understanding of the natural course of these diseases. 
Patients and methods 
GSD patients treated by L T 
A total of 25 patients with GSD types I, III, and IV having received 
a L T are known to us. Information on 6 of these patients was only 
available from the literature [I, 7, 14, IS, 23], while the remai~ing 
IS are followed by the authors [8, 9, 13, 19). The occurrence of hver 
adenoma bearing the risk for malignant transformati~n was the 
reason to opt for transplantation in seven patie~ts WIth GSDIa 
(two females: L T at ages 16.5 and 23 years respectIvely; five males: 
LT at !l.S, 18.9,26.8,27.1 and 27.5 years respectively) (Table I). 
In four of these patients this decision was additionally based on 
poor metabolic control despite conventional treatment efforts. ~he 
26.7-year-old male patient had received a combmed hver and kid-
ney transplant (case 3, Table I). A second L T combined wit? a 
renal transplant was necessary in the 16.5-year-old female patIent 
when she was 30.5 years of age (case 1, Table I). Two female pa-
tients with GSDIb (7.6 and 13.8 years old) received a liver trans-
plant solely on the basis of ineffective dietary treatment (Table I). 
Three patients with GSD type III, a 32.5-year-ol~ female (GSD 
TUb) with liver cirrhosis and hepatocellular carcmoma [13], ~ 
44-year-old male with liver failure [J. Moser, personal commUnI-
cation], and another female [25) received liver transplants. The 
indication was not reported for the latter patient. 
All 13 patients with GSD type IV who had received a liver 
transplant and for whom information was available, were male [\,8, 
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19, 23, 24] (Table 2). The two youngest were transplanted at II 
months of age and the oldest at 12 years (mean age: 3.2 years). The 
indication for L T was based on the occurrence of liver failure in all 
cases, and for one patient also on the presence of liver adenoma. 
GSD type I patients treated conventionally 
This popUlation consists of 29 GSDla patients and one GSDlb 
patient older than 17 years of age. All patients are being followed at 
Duke University Medical Center. They were divided into three 
groups according to age at initiation of night-time nasogastric tube 
feeding or cornstarch treatment. \.) "Early": 13 patients (including 
the one GSDlb patient) who were diagnosed and started on dietary 
treatment within the first 2 years of life (average age: 21.0 years; age 
range: 17.3 - 26.0 years; 8 females); 2.) "intermediate": seven .pa-
tients treated as of 2 to IS years old (average age: 25.2 years; age 
range: 17.8 - 32.2 years; 4 females); and 3.) "Iate"; ten patients who 
were either diagnosed late and treatment did not begin before IS 
years old and/or who were not compliant (average age: 34.5 years; 
age range: 25.5 - 48.4 years; 3 females). Success of treatment was 
assessed using the occurrence and number of adenoma and pres-
ence or level of proteinuria as parameters. 
ResuHs and discussion 
GSD type I 
Seven patients with GSDIa and two with GSDIb have 
received liver transplants (mean age 19.2 years, range 
7.6-27.5 years) because of multiple liver adenomas 
bearing the risk of malignant transformation, and/or 
poor metabolic control. None, however, had carcinomas 
confirmed in the explanted livers. All patients are alive 
0.5 to 11.3 years post-transplant (Table 1). Hypogly-
cemia, hyperuricemia, hyperlactic acidemia and hype-
rlipidemia have been corrected in all of these patients, 
liberating them from their strict dietary regimen. Catch-
up growth, however, was observed in only two patients. 
Normal growth before and after transplantation was 
reported for one GSDla and one GSDlb patient while 
for two, no benefit of transplantation on growth was 
documented. No information on growth development 
was available for the remaining three patients. 
Whether L T results in reversal and/or prevention of 
renal disease remains unclear. The first GSDla patient to 
receive a liver transplant in 1982 (case 1, Table 1) [15], 
required a second liver transplant 14 years after the first, . 
at age 30.5 years. This was necessary since she had de-
veloped end-stage liver cirrhosis secondary to hepatitis 
C, which was most likely acquired via an infected blood 
transfusion. By this time, she had also developed chronic 
renal failure (serum creatinine 1.6-3.3 mg/dl, BUN 29-
48 mg/dl, creatinine clearance 20-30 ml/min/l. 73 m2, 
oliguria) with only mild proteinuria (192 mg/24 h), and 
was treated with a combined liver re-transplantation and 
kidney transplantation. Ultrasound had excluded 
nephrolithiasis and calcinosis. Renal failure was attrib-
uted to interstitial kidney disease due to cyc1osporin A 
nephrotoxicity. This diagnosis was based on the kidney 
function tests and only minimal proteinuria. A renal 
biopsy was not performed. Renal impairment in GSD 
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type I is usually manifested by focal segmental glo-
merulosclerosis of which hyperfiltration and proteinuria 
are early signs [5]. The second liver transplant recipient 
with GSD type I (case 3, Table 1) had received a com-
bined liver and kidney transplant at age 26.7 years. One 
GSDIb patient (case 8, Table 1) had a decreased inulin 
(59 ml/min/1.73 m2; normal: 126 ± 30 ml/min/1.73 m2) 
and PAH clearance (369 ml/min/1.73 m2; normal: 
648 ± 168 ml/min/1.73 m2) as well as increased albu-
min/creatinine ratio (7.5 mg/mmol; normal: < 2 mg/ 
mmol) prior to L T. Four years post-transplant, this pa-
tient's PAH (508 ml/min/1.73 m2) and albumin/creati-
nine ratio (3.1 mg/mmo!) have improved, and the inulin 
clearance (60 ml/min/1.73 m2) has remained stable 
(A. Lachaux, personal communication). All other GSDI 
patients have been followed for a maximum of 6.8 years 
and have not presented any sign of renal disease to date. 
Patients with GSDlb benefit from L T by gaining 
metabolic control. Neutropenia. however, may persist 
and infections may recur after transplantation necessi-
tating continuous administration of granulocyte colony 
stimulating factor [9]. 
In the last 20 years, significant improvement in the 
diagnosis and treatment of GSD-I has been achieved. 
The benefit of early initiation of treatment is demon-
strated in 30 GSDI patients older than 17 years. They 
were divided into three groups depending on the indi-
vidual onset of night-time nasogastric tube feeding 
or cornstarch administration. These, however, small 
groups, were compared with respect to the presence of . 
proteinuria and liver adenoma. It is noteworthy that 
only one patient in the early treatment group, who died 
at 20.2 years of age, had developed GSD related renal 
insufficiency necessitating a kidney transplant (Fig. 1). 
This patient had a history of recurrent urinary tract in-
fections and pyelonephritis [5, 6]. The percentage of pa-
tients without proteinuria is highest in the early treated 
group. This observation is supported by the results of a 
recently published study on metabolic control and renal 
dysfunction in GSDI patients [26]. The incidence of liver 
adenoma is also more rare in patients who were treated 
already within the first 2 years of life, which further 
suggests that early treatment is beneficial (Fig. 2). None 
of the patients had developed signs of malignant liver 
tumors as screened for regularly by abdominal ultra-· 
sound and computer tomography as well as determina-
tion of serum cx-fetoprotein levels. However, the 
reliability of these tests to detect malignant transforma-
tion in an early stage has not yet been proven. LT should, 
therefore, be considered for those GSDI patients with 
findings highly suggestive of malignant liver tumors. A 
combined liver and kidney transplantation may be indi-
cated when renal function is already compromised. 
GSD type III 
The first report on LT in GSD type III did not provide 
details on the patient [25]. The second report describes a 
Fig. 1 Effect of age at treat-
ment initiation on renal func-
tion as expressed by proteinuria 
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32-year-old with GSDIIIb who underwent L T because 
of end-stage cirrhosis [13]. A hepatocellular carcinoma 
was also found in the explanted liver. At 4.2 years after 
transplantation, the patient has normal liver function 
and metabolic control without any restrictions, and re-
mains on prednisone, cyclosporin A, and azathioprine 
for prophylaxis of graft rejection. She continues to have 
no signs of myopathy or cardiomyopathy. A third pa-
tient with GSDIII was transplanted when 44 years old 
following the development of liver failure. His ex planted 
liver was negative for both, benign and malignant tu-
mors (1. Moser, personal communication). 
Liver fibrosis is a common feature of GSD type III, 
and in some cases micro nodular cirrhosis has been 
found. In most cases, the fibrosis/cirrhosis appears not 
to progress. However, overt liver cirrhosis with portal 
hypertension and bleeding esophageal varices have been 
observed. Liver adenoma can occur in GSD type III but 
malignant transformation has not yet been reported. 
Hepatocellular carcinoma in the absence of adenoma 
has been observed in three cases [13, 22, Y-T. Chen, 
personal communication]. LT is indicated when end-
stage cirrhosis and/or hepatocellular carcinoma are de-
tected. As GSD type III is a multi-system disorder (type 
IIIa), the long-term success of L T particularly with re-
gard to myopathy/cardiomyopathy is not known. A 
non-invasive DNA based diagnosis can be used to 
identify patients having only liver involvement (IIIb) 
[21]. 
Fig. 2 Effect of age at treat-
ment initiation on the occur-
rence of liver adenomas 
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GSD type IV 
Clinical data are available on 13 patients who underwent 
L T (Table 2). All patients were male with two sets of 
brothers (cases 2, 6, and 5, 7). The mean age at the time 
of transplantation was 3.2 years (range 0.9-12 years). All 
patients showed progressive liver cirrhosis with evidence 
of portal hypertension at the time of transplantation. 
Two died immediately after transplantation (days 3 and 
36); one died 9 months post transplantation from heart 
failure [23]; the other died 5.5 years post-transplant from 
meningococcal sepsis while on long-term immunosup-
pressants (prednisone, cyclosporin A). Ten patients have 
not had neuromuscular or cardiac complications during 
follow-up periods for as long as l3.5 years. Remarkably, 
there was a reduction in the amount of amylopectin 
on myocardial biopsy in one of these patients (case 5, 
Table 2) [24]. This was attributed to cells migrating from 
the donor liver to the heart, acting as enzyme couriers. 
The absence of cardiac symptoms in these patients 
contrasts to case 3 who died 9 months post L T from 
heart failure with pathological infiltration of amylopec-
tin [23]. This patient had mild left ventricular hyper-
trophy on ECG but a normal echocardiogram prior to 
L T. Possibly he had irreversible cardiac involvement 
pre-transplantation, although this remains speculative. 
Four patients with the non-progressive hepatic form 
of GSD type IV previously reported and now at ages 5, 
7, IS, and 22 years old, continued to have normal liver 
<3 adenoma :8 adenoma 
Treatment Group 
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• intennediate 
o late 
<D: number of patients 
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function and no skeletal muscle, cardiac or neurological 
involvement, despite significant deficiency of branching 
enzyme activity [16]. Mutation analysis showed that 
both hepatic and neuromuscular forms of GSD-IV are 
caused by mutations in the same glycogen branching 
enzyme gene [2]. The mutant alleles in patients with the 
fatal neonatal neuromuscular form and with the pro-
gressive hepatic form resulted in diminished branching 
enzyme activity in the transient expression system. Two 
patients with the non-progressive hepatic form carry a 
missense mutant allele (Y329S), which exhibits 45% of 
br2.nching enzyme activity. This mutation was not de-
tected in 35 unrelated normal individuals or in patients 
with the more severe forms of GSD type IV [2]. Further 
study of genotype-phenotype correlations may yield 
useful information in predicting the clinical outcome 
regarding the prognosis and necessity of an eventual LT. 
Liver transplantation should be considered a treatment 
option for those patients with hepatic GSD who devel-
oped liver malignancy or failure, and for GSD type IV 
patients with clearly the classical and progressive hepatic 
form. It needs to be remembered that transplantation may 
only improve the hepatic aspect of GSD while in patients 
with GSD type lIla or type IV, it may progress in other 
organs, namely the heart, skeletal muscle and nervous 
system, which may be deleterious. It remains to be eval-
uated, whether a geQotype-phenotype correlation exists 
for GSD type IV, which may aid in decision making. 
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